AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study



Status:Archived
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2009
End Date:December 2011

Use our guide to learn which trials are right for you!


Chronically total occlusions (CTO) are difficult to treat and have high risk for restenosis.
Although everolimus-eluting stents (EES) are very promising for the treatment of CTOs due to
their low late loss and excellent deliverability, there are currently no published data on
EES implantation in CTOs.

The specific aim of this proposal is to examine the 8-month incidence of binary angiographic
in-stent restenosis (defined as a stenosis of >50% of the minimum lumen diameter of the
target stent) after implantation of the EES in CTO.

It is the investigators hypothesis that EES-treated CTO lesions will have ≤20% 8-month
in-stent binary angiographic restenosis rate.



We found this trial at
1
site
4500 S. Lancaster Rd.
Dallas, Texas 75216
800-849-3597
Dallas VA Medical Center VA North Texas Health Care System (VANTHCS) is a progressive health...
?
mi
from
Dallas, TX
Click here to add this to my saved trials